Hydralazine Hydrochloride Injection
Product Images NDC 51662-1376

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Hydralazine Hydrochloride (NDC 51662-1376). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pouch Labeling (51662 1376 2 Pouch Labeling)

Hydralazine Hydrochloride Injection, USP is a prescription medication used for intramuscular or intravenous administration to patients who are unable to take oral medication. The injection comes in a 1mL vial with a concentration of 20mg per mL. The medication is sterile and is to be discarded after single-use. The usual dosage should be determined by consulting the package insert. The drug must be stored at a temperature between 20° to 25°C (68° to 77°F) and is available only for emergency use. Readers are advised to refer to the manufacturer’s package insert for complete information. The product is manufactured by HF Acquisition Co., LLC, Mukilteo, WA 98275.*

FDA Label Image

Box Labeling (51662 1376 3 Box Labeling)

Hydralazine Hydrochloride Injection is a medication used for IM or IV use in emergency situations for patients who are unable to take oral medication. It comes in a 1mL vial with 20mg per mL potency, in a box of 25 vials. The unused portion of the medication should be discarded. The dosage information and storage guidelines are provided in the package insert. It is a sterile and controlled temperature medication. The original manufacturer of the medication is HF Acquisition Co., LLC, located in Mukilteo, WA. NIDICP, E0, EPX, and other alphanumeric characters are not applicable or understandable.*

FDA Label Image

Serialized Labeling (51662 1376 3 Serialized Labeling)

FDA Label Image

How Supplied (How Supplied)

This is a description of a pharmaceutical product called Hydralazine Hydrochloride Injection, USP. It comes in a single dose vial containing 20 mg per mL and a 1 mL fill. Each tray contains 25 vials of 1 or 2 mL. The product has an NDC code of 63323-614-0.*

FDA Label Image

Logo (Logo)

This is a partial address and does not provide enough information to generate a useful description.*

FDA Label Image

Serialized Labeling (Serialized Labeling)

This is the description of a pharmaceutical product called "hydrALAZINE Hydrochloride Injection USP". It is an injectable solution that contains 20 mg per mL for intramuscular or intravenous administration. The packaging includes a single dose vial and a warning to discard any unused portion. The manufacturer is HF Acquisition Co. LLC, located in Mukilteo, Washington, and information on usage can be found in the package insert.*

FDA Label Image

Structure (Structure)

CgHgNs * HCI M.W. 196.64 is a chemical formula and molecular weight of a compound. However, without further context, it is not possible to identify the compound or provide a useful description.*

FDA Label Image

Vial Label (Vial Label Updated)

hydrALAZINE Hydrochloride Injection is a prescription medication used for the treatment of high blood pressure. Each vial contains 20 mg of the medication for a single-dose use only. The medication should be discarded if not used entirely. No further information is available from the given text.*

FDA Label Image

Vial (Vial Labeling)

This is a description of a medication called Hydralazine Hydrochloride Injection, USP. The medication is available in single-dose vials and each vial contains 20 mg of the medication. The recommended route of administration is either intravenous or intramuscular. The packaging contains a warning to discard any unused portion of the medication.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.